The latest update is out from Myomo ( (MYO) ).
On April 10, 2025, Myomo announced that directors Amy Knapp and Yitzchak Jacobovitz will not seek re-election at the upcoming 2025 Annual Meeting. Their departure marks a transition in the company’s board, with plans to appoint new directors to enhance governance and strategic oversight. The announcement reflects confidence in Myomo’s strategic direction and financial position, with both directors expressing optimism about the company’s future, including its Medicare Part B coverage achievement for the MyoPro product.
Spark’s Take on MYO Stock
According to Spark, TipRanks’ AI Analyst, MYO is a Neutral.
Myomo’s strong revenue growth and positive earnings call sentiment are significant strengths. However, the lack of profitability, negative cash flows, and bearish technical indicators are key risks. The stock’s valuation suggests potential overvaluation, contributing to a moderate overall score.
To see Spark’s full report on MYO stock, click here.
More about Myomo
Myomo, Inc. is a wearable medical robotics company that develops and markets the MyoPro product line, which is a powered upper-limb orthosis designed to restore function to weakened or paralyzed arms. It serves patients suffering from neurological disorders and upper-limb paralysis, enabling them to perform daily activities independently. Headquartered in Burlington, Massachusetts, Myomo operates across the U.S. and has international representatives.
YTD Price Performance: -27.78%
Average Trading Volume: 423,324
Technical Sentiment Signal: Buy
Current Market Cap: $160.9M
See more insights into MYO stock on TipRanks’ Stock Analysis page.